Literature DB >> 17635872

Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection.

Ellen Marks1, Martina Verolin, Anneli Stensson, Nils Lycke.   

Abstract

Th1 cells and gamma interferon (IFN-gamma) production play critical roles in protective immunity against genital tract infections by Chlamydia trachomatis. Here we show that inducible costimulatory molecule (ICOS)(-/-) mice develop greatly augmented host resistance against chlamydial infection. Protection following a primary infection was characterized by strong Th1 immunity with enhanced CD4(+) T-cell-mediated IFN-gamma production in the genital tract and high expression of T-bet in the draining para-aortic lymph node. This Th1 dominance was associated with low expression of interleukin 10 (IL-10) mRNA in the uteruses of protected ICOS(-/-) mice. By contrast, CD28(-/-) mice were severely impaired in their adaptive immune response, demonstrating a lack of CD4(+) T cells and IFN-gamma in the genital tract, with a substantial delay in bacterial elimination compared to that seen in wild-type (WT) mice. Upon reinfection, WT mice exhibited a transient local infection with evidence of regulatory T-cell (Treg)/Foxp3 mRNA and a more balanced Th1 and Th2 response in the genital tract than ICOS(-/-) mice, whereas 90% of the latter mice developed sterile immunity, poor expression of local Treg/Foxp3 mRNA, and macroscopic signs of enhanced local immunopathology. Therefore, different requirements for CD28 signaling and ICOS signaling clearly apply to host protection against a genital tract infection by C. trachomatis. Whereas, CD28 signaling is critical, ICOS appears to be dispensable and can have a dampening effect on Th1 development by driving Th2 immunity and anti-inflammation through IL-10 production and promotion of the Foxp3(+) Treg populations in the genital tract. Both the CD28-deficient and the ICOS-deficient mice demonstrated poor specific antibody production, supporting the fact that antibodies are not needed for protection against genital tract chlamydial infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635872      PMCID: PMC1951167          DOI: 10.1128/IAI.00465-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  56 in total

1.  CD28 costimulation prevents cell death during primary T cell activation.

Authors:  P J Noel; L H Boise; J M Green; C B Thompson
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

2.  Complement C1q and C3 are critical for the innate immune response to Streptococcus pneumoniae in the central nervous system.

Authors:  Tobias A Rupprecht; Barbara Angele; Matthias Klein; Juergen Heesemann; Hans-Walter Pfister; Marina Botto; Uwe Koedel
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

3.  Differential T cell costimulatory requirements in CD28-deficient mice.

Authors:  A Shahinian; K Pfeffer; K P Lee; T M Kündig; K Kishihara; A Wakeham; K Kawai; P S Ohashi; C B Thompson; T W Mak
Journal:  Science       Date:  1993-07-30       Impact factor: 47.728

4.  CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract.

Authors:  H Su; H D Caldwell
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Identification and distribution of the costimulatory receptor CD28 in the mouse.

Authors:  J A Gross; E Callas; J P Allison
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

6.  Cofactors in male-female sexual transmission of human immunodeficiency virus type 1.

Authors:  F A Plummer; J N Simonsen; D W Cameron; J O Ndinya-Achola; J K Kreiss; M N Gakinya; P Waiyaki; M Cheang; P Piot; A R Ronald
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

7.  Studies with MHC-deficient knock-out mice reveal impact of both MHC I- and MHC II-dependent T cell responses on Listeria monocytogenes infection.

Authors:  C H Ladel; I E Flesch; J Arnoldi; S H Kaufmann
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

8.  Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces.

Authors:  B Haneberg; D Kendall; H M Amerongen; F M Apter; J P Kraehenbuhl; M R Neutra
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

9.  Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction.

Authors:  S J Klaus; L M Pinchuk; H D Ochs; C L Law; W C Fanslow; R J Armitage; E A Clark
Journal:  J Immunol       Date:  1994-06-15       Impact factor: 5.422

10.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H D Caldwell; J Kromhout; J Schachter
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

View more
  18 in total

1.  Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection.

Authors:  Norma Olivares-Zavaleta; William Whitmire; Donald Gardner; Harlan D Caldwell
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

Review 2.  Fighting Persistence: How Chronic Infections with Mycobacterium tuberculosis Evade T Cell-Mediated Clearance and New Strategies To Defeat Them.

Authors:  Laurisa Ankley; Sean Thomas; Andrew J Olive
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

3.  The female lower genital tract is a privileged compartment with IL-10 producing dendritic cells and poor Th1 immunity following Chlamydia trachomatis infection.

Authors:  Ellen Marks; Miguel A Tam; Nils Y Lycke
Journal:  PLoS Pathog       Date:  2010-11-04       Impact factor: 6.823

4.  Distinct roles of CD28- and CD40 ligand-mediated costimulation in the development of protective immunity and pathology during Chlamydia muridarum urogenital infection in mice.

Authors:  Lili Chen; Wen Cheng; Pooja Shivshankar; Lei Lei; Xiaoyun Zhang; Yimou Wu; I-Tien Yeh; Guangming Zhong
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

5.  CD28 costimulation is essential for human T regulatory expansion and function.

Authors:  Tatiana N Golovina; Tatiana Mikheeva; Megan M Suhoski; Nicole A Aqui; Victoria C Tai; Xiaochuan Shan; Ronghua Liu; R Robert Balcarcel; Nancy Fisher; Bruce L Levine; Richard G Carroll; Noel Warner; Bruce R Blazar; Carl H June; James L Riley
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

Review 6.  Immunopathogenesis of Chlamydial Infections.

Authors:  Ashlesh K Murthy; Weidang Li; Kyle H Ramsey
Journal:  Curr Top Microbiol Immunol       Date:  2018       Impact factor: 4.291

7.  Identification of dendritic cell subsets responding to genital infection by Chlamydia muridarum.

Authors:  Raymond J Moniz; Ann M Chan; Kathleen A Kelly
Journal:  FEMS Immunol Med Microbiol       Date:  2009-01-12

8.  CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract.

Authors:  David C Gondek; Andrew J Olive; Georg Stary; Michael N Starnbach
Journal:  J Immunol       Date:  2012-08-01       Impact factor: 5.422

9.  Modulation of cytokines and transcription factors (T-Bet and GATA3) in CD4 enriched cervical cells of Chlamydia trachomatis infected fertile and infertile women upon stimulation with chlamydial inclusion membrane proteins B and C.

Authors:  Rishein Gupta; Harsh Vardhan; Pragya Srivastava; Sudha Salhan; Aruna Mittal
Journal:  Reprod Biol Endocrinol       Date:  2009-08-22       Impact factor: 5.211

10.  Decreased expression of T-cell costimulatory molecule CD28 on CD4 and CD8 T cells of mexican patients with pulmonary tuberculosis.

Authors:  German Bernal-Fernandez; Patricia Espinosa-Cueto; Rosario Leyva-Meza; Nathalie Mancilla; Raul Mancilla
Journal:  Tuberc Res Treat       Date:  2010-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.